LINDSAY A MD ROSENWALD
CIK 941841 · PRESIDENT, CEO & CHAIRMAN · last filed 2026-06-26
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$89.03M
Companies
9
Total Filings
102
Lifetime Open-Market Net
$12.02M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| DERM | Director | 397,616 | $6.31 | $2.51M | $321.4K | 8 | 2026-06-26 |
| FBIOP | PRESIDENT, CEO & CHAIRMAN | 4,586,841 | $18.76 | $86.05M | $7.68M | 24 | 2026-03-20 |
| Checkpoint Therapeutics, Inc. (CKPT) Delisted | Director | 157,007 | $4.26 | $668.8K | $356.2K | 12 | 2025-05-30 |
| AVENUE THERAPEUTICS, INC. (ATXI) Delisted | Director | 4,724 | $0.35 | $1.7K | $543.7K | 7 | 2024-09-25 |
| MBIO | Director | 1,210 | $0.63 | $764 | $758.1K | 12 | 2023-07-07 |
| FBIO | PRESIDENT, CEO | 8,000 | $3.39 | $27.1K | $1.01M | 6 | 2017-11-08 |
| Origo Acquisition Corp (CNLM.W) Delisted | Co-Chairman and CEO | 265,000 | — | — | $0 | 2 | 2016-05-23 |
| Fortress Biotech, Inc. (CNDO) Delisted | President and CEO | 4,962,304 | — | — | $1.36M | 16 | 2014-12-03 |
| NVD | 10%+ Owner | 85,506 | $5.22 | $446.3K | $0 | 1 | 2007-01-23 |
Recent Filings · Page 2 of 11
102 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-07-11 | FBIOP | Buy (P) | +5,000 | $37.0K | EDGAR |
| 2024-07-10 | DERM | Grant (A) | +9,728 | $0 | EDGAR |
| 2024-07-10 | FBIOP | Buy (P) | +5,000 | $36.8K | EDGAR |
| 2024-07-01 | FBIOP | Buy (P) | +20,000 | $32.7K | EDGAR |
| 2024-05-20 | FBIOP | Buy (P) | +10,000 | $17.6K | EDGAR |
| 2024-05-16 | Checkpoint Therapeutics, Inc. (CKPT) Delisted | Grant (A) | +82,051 | $0 | EDGAR |
| 2024-03-27 | DERM | Buy (P) | +10,000 | $30.4K | EDGAR |
| 2024-03-25 | DERM | Buy (P) | +20,000 | $68.0K | EDGAR |
| 2024-01-09 | FBIOP | Buy (P) | +50,000 | $118.8K | EDGAR |
| 2024-01-03 | FBIOP | Grant (A) | +216,465 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.